Floatz logo

Talquetamab

Hematopoietic And Lymphoid System Neoplasm

Janssen Research & Development, LLCmonoclonal_antibodyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

133 Active assets in the Hematopoietic And Lymphoid System Neoplasm cohort.

Asset / SponsorPhaseRating
Adriamycin
OHSU Knight Cancer Institute
Phase 4BBB
Dexasone
City of Hope Medical Center
Phase 3BB
Teclistamab
Janssen Pharmaceutical K.K.
Phase 2BB
Bortezomib
OHSU Knight Cancer Institute
Phase 4BB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

Talquetamab is also rated in:

plasma cell myelomaActive
BB
Indicative · Phase 4
67 / 100
View asset →
Waldenstrom macroglobulinemiaActive
BB
Indicative · Phase 4
65 / 100
View asset →
plasma cell leukemiaActive
CCC
Indicative · Phase 3
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →